The higher risk of AML transformation compared to non-R882 mutant cases suggests that DNMT3A R882 mutant MDS cases, even ones without excess blasts at initial diagnosis, probably should be managed differently from non-R882 mutant MDS cases. The gene discussed is DNMT3A; the disease is myelodysplastic syndrome.